breast cancer

Negligible Benefit Of Nerlynx, A New Breast Cancer Drug, Calls For Caution In Prescribing
Forbes
Fri, 11/17/17 - 11:10 am
Nerlynx
breast cancer
Puma Biotechnology
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
Yahoo/Zacks.com
Thu, 11/16/17 - 11:13 am
AstraZeneca
Faslodex
FDA
breast cancer
Verzenio
Eli Lilly
Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations
Fierce Pharma
Thu, 11/16/17 - 11:07 am
Pfizer
Ibrance
Novartis
Kisqali
England
breast cancer
UK
NICE
Novartis takes fight to Pfizer's Ibrance with new Kisqali data
Yahoo/Reuters
Wed, 11/8/17 - 10:10 am
Novartis
Pfizer
Ibrance
Kisqali
breast cancer
FDA puts Roche's Perjeta-Herceptin combo in the fast lane, but will it deliver?
Fierce Pharma
Fri, 09/29/17 - 10:08 am
FDA
Roche
Perjeta-Herceptin
breast cancer
Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval
Fierce Pharma
Thu, 09/28/17 - 06:24 pm
Eli Lilly
Pfizer
Novartis
Verzenio
breast cancer
Ibrance
Kisqali
Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst
Fierce Pharma
Thu, 09/21/17 - 10:18 pm
Pfizer
Ibrance
breast cancer
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
BioPharma Dive
Mon, 09/18/17 - 09:23 am
Samsung Bioepis
EMA
Europe
biosimilars
Herceptin
Roche
breast cancer
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
Endpoints
Mon, 09/11/17 - 09:17 am
ESMO
Eli Lilly
Pfizer
Novartis
abemaciclib
breast cancer
Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England?
Fierce Pharma
Thu, 08/24/17 - 05:11 pm
Novartis
Kisqali
Pfizer
Ibrance
reimbursement
breast cancer
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
Yahoo/Zacks.com
Wed, 08/23/17 - 11:14 am
Pfizer
Ibrance
breast cancer
Faslodex
AstraZeneca
New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet
Fierce Pharma
Mon, 08/7/17 - 01:32 pm
Novartis
Kisqali
Pfizer
Ibrance
breast cancer
Does Puma's quick Nerlynx launch play into its buyout prospects?
Fierce Pharma
Tue, 08/1/17 - 11:30 am
Puma Biotechnology
Nerlynx
breast cancer
M&A
Does Puma Biotechnology's Approval Make It Worth More?
Motley Fool
Wed, 07/19/17 - 10:00 am
Puma Biotechnology
Nerlynx
breast cancer
Puma granted broad label for neratinib after FDA OK
BioPharma Dive
Wed, 07/19/17 - 09:31 am
Puma Biotechnology
neratinib
breast cancer
Nerlynx
Puma wins big FDA OK for neratinib after running the gamut with investors
Endpoints
Mon, 07/17/17 - 06:50 pm
Puma Biotechnology
neratinib
breast cancer
Nerlynx
Lilly revs up to challenge Pfizer, Novartis in breast cancer with abemaciclib 'priority' nod
Fierce Pharma
Tue, 07/11/17 - 09:56 am
Eli Lilly
Pfizer
Novartis
breast cancer
abemaciclib
Ibrance
Kisqali
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
ASCO17: AstraZeneca pumps up expectations on near-term cancer drug wins, looking to shed a rep for failure
Endpoints
Tue, 06/6/17 - 09:44 am
AstraZeneca
ASCO 2017
Lynparza
breast cancer
Novartis, IBM Watson collab to optimize care for patients with advanced breast cancer
Drug Delivery Business News
Mon, 06/5/17 - 12:07 pm
Novartis
IBM Watson
advanced breast cancer
patients
breast cancer

Pages